Abstracts tagged "IgG4 Related Disease"

Abstract Number: 0032 • ACR Convergence 2025
Protein Language Model-Guided Homology Identifies Microbial Enzymes Linked to Fibrosis-Prone IgG4-RD and Crohn’s Disease
Kumar Thurimella¹, Ahmed Mohamed², Chenhao Li³, Tommi Vatanen⁴, Daniel Graham³, Roisin Owens⁵, Sabina Leanti La Rosa⁶, Damian Plichta³, Sergio Bacallado⁵ and Ramnik Xavier⁷, ¹University of Colorado School of Medicine, Aurora, CO, ²Broad Institute, Boston, ³Broad Institute, Cambridge, MA, ⁴University of Helsinki, Helsinki, Finland, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶NMBU, As, Norway, ⁷Harvard Medical School, Boston, MA
Background/Purpose: Uncharacterized microbial enzymes in metagenomics are difficult to annotate, especially in fibrosis-prone conditions like IgG4-related disease (IgG4-RD) and Crohn’s disease (CD), where microbial carbohydrate…
Abstract Number: 1666 • ACR Convergence 2025
Treatment with Rilzabrutinib was associated with Rapid and Sustained Reduction in Disease Activity in Patients with IgG4-RD Previously Treated or Naïve to B cell Depletion
John Stone¹, Mollie Carruthers², Alireza Meysami³, Matthew Charles Baker⁴, Daniela Ghetie⁵, Lindsay Lally⁶, Fernando Martinez-Valle⁷, Lorenzo Dagna⁸, nicolas schleinitz⁹, Jeea Choi¹⁰, Leda Mannent¹¹ and Owen Hagino¹⁰, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²Vancouver General Hospital, Vancouver, BC, Canada, ³Henry Ford Health, Detroit, MI, ⁴Stanford University, Menlo Park, CA, ⁵Oregon Health and Science University, Portland, OR, ⁶Hospital for Special Surgery, NEW YORK, NY, ⁷Vall d’Hebron Hospital, Barcelona, Spain, ⁸IIRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, ⁹Aix Marseille university, AP-HM, Marseille, France, ¹⁰Sanofi, Morristown, NJ, ¹¹Sanofi, Gentilly, France
Background/Purpose: IgG4-RD is a progressive, immune-mediated fibrotic disease with limited treatment options. Rilzabrutinib is a reversible, orally available inhibitor of Bruton's tyrosine kinase (BTKi). Here,…
Abstract Number: 1190 • ACR Convergence 2025
IgG4-related disease with comorbid autoimmune diseases: a retrospective study from a large cohort
Xinli Yang¹, Wen Zhang², Jiaxin zhou³ and Yuxue Nie⁴, ¹Peking Union Medical College, Dong Cheng Qu, China (People's Republic), ²Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ³Peking Union Medical College Hospital, Beijing, China (People's Republic), ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, Dong Cheng Qu, China (People's Republic)
Background/Purpose: This study aimed to explore the clinical characteristics, treatment, and prognosis of IgG4-related disease (IgG4-RD) patients with comorbid autoimmune diseases (AIDs).Methods: A total of…
Abstract Number: 1173 • ACR Convergence 2025
Prevalence of Coronary Artery Involvement in IgG4-Related Disease Detected by Non-Gated Cross-Sectional Imaging
Matthew Charles Baker¹, Lauren Taylor², Haziq Siddiqi², Jison Hong² and Brian Pogatchnik², ¹Stanford University, Menlo Park, CA, ²Stanford University, Stanford, CA
Background/Purpose: IgG4-related disease (IgG4-RD) classically presents with a mass or diffusely enlarged organ, but it also affects blood vessels of all sizes. Coronary artery involvement…
Abstract Number: 1172 • ACR Convergence 2025
A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients with IgG4-Related Disease
Matthew Charles Baker¹, Audra Horomanski², Robert Fairchild³, Yuhan Liu³, Mariani Diaz Deluna³, Tobias Lanz⁴, Saurabh Gawde³, Mehdi Khalighi³, Benjamin Franc³, Mrudula Penta³, Nancy Pham³ and Kip Guja³, ¹Stanford University, Menlo Park, CA, ²Stanford University, Palo Alto, CA, ³Stanford University, Stanford, CA, ⁴Stanford University, Stanford
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic, systemic, immune-mediated disease that is commonly treated with B cell depletion. However, due to potential risks associated with…
Abstract Number: 1167 • ACR Convergence 2025
Clinical Characteristics and Outcomes of IgG4-Related Disease Patients Who Chose Watchful Observation without Treatment Intervention: A Single-Center Study
Kanako Chujo¹, Hiromi Shimada², Shusaku Nakashima², Taichi Miyagi¹, Koichi Sugihara², Yusuke Ushio¹, Mao Mizusaki², Naoto Manabe¹, Mayuko Wada², Risa Wakiya³, Hiroki Ozaki⁴ and Hiroaki Dobashi², ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, ³Division of Rheumatology, Departent of Internal Medicine, Toho University School of Medicine, Tokyo, Japan, ⁴KKR Takamatsu Hospital, Takamatsu, Kagawa, Japan
Background/Purpose: Treatment of IgG4-related disease (IgG4-RD) is recommended for patients with severe organ involvement or for patients with reduced quality of life even in the…
Abstract Number: 2546 • ACR Convergence 2025
Diagnostic Journey, Clinical Burden, And Quality Of Life Of Patients With IGg4-Related Disease: Results Of A Cross-Sectional Survey Of Patients And Physicians In The United States
Yasmin Hernandez-Barco¹, Jenny Y. Park², Rajvi Wani³, Andrea Meyers⁴, Matthew Charles Baker⁵, Leonard Calabrese⁶, Kristina Patterson², Hannah Connolly⁷, Shiva Lauretta Birija⁷ and Emma Culver⁸, ¹Massachusetts General Hospital; Harvard Medical School, Boston, MA, ²Amgen Inc., Thousand Oaks, CA, ³Amgen Canada Inc., Mississauga, ON, Canada, ⁴Amgen Canada Inc., Thousand Oaks, ON, Canada, ⁵Stanford University, Menlo Park, CA, ⁶Cleveland Clinic, Cleveland, OH, ⁷Adelphi Real World, Bollington, United Kingdom, ⁸John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic immune-mediated fibroinflammatory condition characterized by fibrosis and organ damage. Although IgG4-RD is increasingly recognized, real-world clinical burden remains…
Abstract Number: 1163 • ACR Convergence 2025
Clinical and Biomarker Characteristics of Inebilizumab-Treated Participants Who Experienced an IgG4-RD Flare During the Phase 3 MITIGATE Trial
John Stone¹, Emma Culver², Arezou Khosroshahi³, Wen Zhang⁴, Emanuel Della Torre⁵, Kazuichi Okazaki⁶, Yoshiya Tanaka⁷, Matthias Lohr⁸, nicolas schleinitz⁹, Fernando Martinez-Valle¹⁰, Manu Nayar¹¹, Vinciane Rebours¹², Cory Perugino¹³, Kristen Clarkson¹⁴, Theresa Alexander¹⁴, Xinxin Dong¹⁴, Qian Huang¹⁴, Sue Cheng¹⁴ and Daniel Cimbora¹⁴, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Emory University, Atlanta, GA, ⁴Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁵IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁶Kansai Medical University Kori Hospital, Osaka, Japan, ⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Aix Marseille university, AP-HM, Marseille, France, ¹⁰Vall d’Hebron Hospital, Barcelona, Spain, ¹¹Freeman Hospital, Newcastle upon Tyne, United Kingdom, ¹²Beaujon Hospital, AP-HP, Université Paris-Cité, Clichy, France, ¹³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Amgen, Thousand Oaks, CA
Background/Purpose: IgG4-RD is a rare, chronic, fibroinflammatory disorder characterized by recurrent flares that can affect any organ and lead to permanent tissue damage. Inebilizumab (INEB)…
Abstract Number: 2531 • ACR Convergence 2025
Coronary periarteritis in IgG4-Related Disease
Georges El Hasbani¹, Daniel Larson², Matthew Koster¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester
Background/Purpose: IgG4-related disease (IgG4-RD) is characterized by chronic inflammation and fibrosis, which can affect multiple organs, especially the pancreas, salivary glands, and retroperitoneum (1). It…
Abstract Number: 1154 • ACR Convergence 2025
Assessment Of Damage Using The IgG4-Related Disease Damage Index.
Eduardo Martin-Nares¹ and Gabriela Hernandez-Molina², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Federal District, Mexico
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder affecting multiple organs, often leading to irreversible damage. Standardized tools like the IgG4-RD Damage Index (DI)…
Abstract Number: 2530 • ACR Convergence 2025
Broad Screening of Inflammation-Associated Proteins Identifies Serum CCL19 and CCL2 as Versatile Biomarkers of Disease Activity in IgG4-Related Disease
Federica Bonaso¹, Bohang Jiang², Laura J. Yockey³, Jesse Akaa⁴, Ian Doyle⁴, Evan Hsu⁵, Courtney Leson⁶, Grace McMahon⁷, Isha Jha⁷, Sydney Montesi⁷, Guy Katz⁷, Shiv Pillai⁸, Pui Lee⁵, John Stone⁹, Zachary Wallace¹⁰ and Cory Perugino¹¹, ¹University of Brescia, ASST Spedali Civili of Brescia, Massachusetts General Hospital, Monza, Italy, ²MGH, Boston, MA, ³MGH, Charlestown, MA, ⁴Massachusetts General Hospital (MGH - Mass General) (MGB), Boston, MA, ⁵Boston Children's Hospital, Newton, MA, ⁶Boston Children's Hospital, Boston, ⁷Massachusetts General Hospital, Boston, MA, ⁸Harvard Medical School, Cambridge, MA, ⁹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ¹⁰Massachusetts General Hospital, Newton, MA, ¹¹Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic immune-mediated disease characterized by mass-forming lesions and organ dysfunction. The smoldering tempo and often asymptomatic nature of IgG4-RD…
Abstract Number: 1036 • ACR Convergence 2025
Factors Associated With Long-term Remission After Drug Discontinuation In IgG4-related Disease: A 3-Year Rule
Yifei Wang¹, Yuxue Nie², Jingna Li³, Jialei Zhang⁴, Qinhuan Luo¹, Xinli Yang⁵, Jialing Jiang¹, Nianyi Zhang⁶, Linyi Peng⁷, Yunyun Fei⁶, Jiaxin zhou⁴ and Wen Zhang⁸, ¹Peking Union Medical College, Beijing, China (People's Republic), ²Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, Dong Cheng Qu, China (People's Republic), ³Peking Union Medical College, Dong Cheng Qu, Beijing, China, ⁴Peking Union Medical College Hospital, Beijing, China (People's Republic), ⁵Peking Union Medical College, Dong Cheng Qu, China (People's Republic), ⁶Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁷PEKING UNION MEDICAL COLLEGE HOSPITAL, Beijing, Beijing, China, ⁸Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic)
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder with multi-organ involvement and elevated serum IgG4 levels. Glucocorticoids (GC) with or without immunosuppressants (IM) are…
Abstract Number: 0775 • ACR Convergence 2024
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in IgG4-Related Disease (MITIGATE): Primary Efficacy and Safety Findings
John Stone¹, Emma Culver², Arezou Khosroshahi³, Wen Zhang⁴, Emanuel Della Torre⁵, Kazuichi Okazaki⁶, Yoshiya Tanaka⁷, Matthias Löhr⁸, Nicolas Schleinitz⁹, Lingli Dong¹⁰, Hisanori Umehara¹¹, Marco Lanzillotta¹², Zachary Wallace¹³, Mikael Ebbo¹⁴, George Webster¹⁵, Ferran Martinez Valle¹⁶, Manu Nayar¹⁷, Vinciane Rebours¹⁸, Cory Perugino¹⁹, Xinxin Dong²⁰, Yanping Wu²⁰, Nishi Rampal²⁰ and Daniel Cimbora²⁰, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²John Radcliffe Hospital, and Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, ³Emory University, Atlanta, GA, ⁴Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁵Ospedale San Raffaele, Milan, Italy, ⁶University of Occupational and Environmental Health, Osaka, Japan, ⁷Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Aix Marseille university, AP-HM, Marseille, France, ¹⁰Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), ¹¹Department of Rheumatology and Immunology, Nagahama City Hospital,, Nagahama, Shiga 526-0043, Japan, Japan, ¹²IRCCS Ospedale San Raffaele, Milano, Italy, ¹³Massachusetts General Hospital, Newton, MA, ¹⁴Aix-Marseille Université, Marseille, France, ¹⁵University College Hospital London, London, United Kingdom, ¹⁶Vall d’Hebron Hospital, Barcelona, Spain, ¹⁷Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ¹⁸Beaujon Hospital, Université Paris-Cité, France, ¹⁹Massachusetts General Hospital, Boston, MA, ²⁰Amgen Inc., Thousand Oaks, CA
Background/Purpose: IgG4-related disease (IgG4-RD) is a rare, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…
Abstract Number: 1113 • ACR Convergence 2024
2nd Analysis of IgG4-Related Disease in a Diverse Long Island Population: Utilizing Serological and Histological Markers for Assessing Treatment Response
Young Min Cho¹, Alejandro Quintero Villegas², Matt Means³, Zanos Theodoros², Lara El Khoury⁴ and Galina Marder³, ¹Northwell, Glen Cove, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Northwell, Manhasset, NY, ⁴Division of Rheumatology/Northwell Health, Great Neck, NY
Background/Purpose: IgG4-RD presents various clinical manifestations, making it challenging to assess treatment responses. B-cell depletion agents such as Rituximab (RTX) are used in refractory cases.…
Abstract Number: 1123 • ACR Convergence 2024
Serological Elevation of IgG4: Clinical Correlation and Differential Diagnosis
Pablo Martínez Calabuig¹, Laura Salvador Maicas², Mireia Lucía Sanmartín Martínez³, Iván Jesús Lorente Betanzos³, Jorge Juan Fragío Gil⁴, Roxana González Mazario⁵, Amalia Rueda⁵, juan José Lerma Garrido⁶, Clara Molina Almela³ and Cristina Campos Fernández⁷, ¹HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ²Consorcio Hospital General Universitario de Valencia, Castellón de la Plana, Comunidad Valenciana, Spain, ³Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ⁴Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, ⁵Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ⁶Hospital General Universitario Valencia, Valencia, Comunidad Valenciana, Spain, ⁷Department of Rheumatology. Hospital General Universitario de Valencia, Valencia, Spain
Background/Purpose: IgG4-related disease (IgG4-RD) is a rare, systemic, immunomediated fibroinflammatory process with uncertain etiology and pathophysiology that can affect multiple organs, presenting common clinical, radiological,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].